[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"psp\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:psp":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,43,77,124],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100611455","digital-health-technologies-for-progressive-supranuclear-palsy-and-dementia-with-lewy-bodies-100611455",false,"NCT07240805","Digital Health Technologies for Progressive Supranuclear Palsy and Dementia With Lewy Bodies","Digital Health Technologies For Monitoring Disease Symptoms in Progressive Supranuclear Palsy and Dementia With Lewy Bodies","Inclusion Criteria:\n\n* Male and female participants aged 40-89 meeting clinical diagnostic criteria for probable PSP, probable MCI-LB or probable DLB.\n* Able to be present for all study procedures, complete questionnaires and assist during home data collection.\n* Eligible participants must be fluent in reading and speaking English and must be capable of providing informed consent based on the principal investigator's judgment.\n* Must have a caregiver or study partner who is willing and able to assist with all study-related procedures.\n* Ambulatory (able to take 10 steps with minimal support such as use of a cane)\n\nExclusion Criteria:\n\n* Any neurological, medical, or psychiatric condition that would preclude or confound participation in study activities based on the investigator's judgment.\n* History of frequent falls defined as more than 5 falls per month, will not be eligible to participate in the study.","ALL","40 Years","89 Years",{"count":20,"type":21},60,"ESTIMATED","OBSERVATIONAL","Progressive supranuclear palsy (PSP), mild cognitive impairment with Lewy bodies (MCI-LB), and Dementia with Lewy Bodies (DLB) are severe neurodegenerative diseases that cause significant motor impairment impacting daily function. Researchers at BioSensics, Johns Hopkins School of Medicine, Massachusetts General Hospital and their collaborators aim to conduct an analytical and clinical validation of wearable-based digital health technologies for monitoring upper and lower limb function in PSP, MCI-LB and DLB that could enable frequent, at-home monitoring and be incorporated into future clinical trials.",[25,26,27,28,29],"Progressive Supranuclear Palsy(PSP)","Dementia With Lewy Bodies (DLB)","PSP","Lewy Body Dementia (LBD)","Lewy Body Disease","NOT_YET_RECRUITING","2026-06-30",{"date":33,"type":34},"2026-07-01","ACTUAL",{"date":36,"type":21},"2026-06-15",{"date":38,"type":21},"2029-01-01",{"name":40,"class":41},"BioSensics","INDUSTRY",2,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":51,"minAge":52,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":54,"phases":55,"briefSummary":57,"conditions":58,"keywords":62,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":72,"leadSponsor":74,"locationsCount":4},"100625929","intraoperative-bupivacaine-injection-to-reduce-acute-and-chronic-pain-after-tvttvt-o-surgery-randomized-double-blind-trial-100625929","NCT07429019","Intraoperative Bupivacaine Injection to Reduce Acute and Chronic Pain After TVT\u002FTVT-O Surgery. Randomized Double-Blind Trial","Reduction of Post-surgery Pelvic Pain by Bupivacaine Injection During TVT\u002F TVT-O Procedure","PAIN-TVT","Inclusion Criteria:\n\n* Women aged 18 years or older\n* Scheduled to undergo vaginal surgery including TVT or TVT-O procedure for stress urinary incontinence\n* Able and willing to provide written informed consent\n* Willing to complete postoperative follow-up assessments for at least 6 months\n\nExclusion Criteria:\n\n* Planned concomitant abdominal, laparoscopic, or robotic surgery\n* Pre-existing chronic pelvic pain\n* Diagnosis of fibromyalgia\n* Diagnosis of endometriosis\n* Inability to complete follow-up assessments\n* Inability to provide informed consent","FEMALE","18 Years",{"count":20,"type":21},"INTERVENTIONAL",[56],"NA","This randomized, double-blind controlled trial will evaluate whether intraoperative injection of bupivacaine at the sling insertion site reduces postoperative pelvic and thigh pain in women undergoing TVT or TVT-O surgery for stress urinary incontinence. Women aged 18 years and older scheduled for vaginal surgery including a mid-urethral sling procedure will be randomly assigned to receive either 0.5% bupivacaine or saline injection at the surgical site at the end of the procedure.\n\nPostoperative pain will be assessed using the Numerical Rating Scale (NRS) within 24 hours after surgery, at one month, and at least six months postoperatively. The study will also evaluate opioid consumption and examine the relationship between early postoperative pain and the development of chronic postsurgical pain. The results may help determine whether local anesthetic injection during sling surgery can improve short- and long-term pain outcomes.",[59,27,60,61],"Pain After Surgery","Chronic Pain Syndrome","Local Anesthesia Infiltration",[63,64,65,66,67],"TVT","TVTO","Mid Urethral Sling","pain","chronic pain syndrom","2026-06-20",{"date":70,"type":34},"2026-06-23",{"date":33,"type":21},{"date":73,"type":21},"2027-10-01",{"name":75,"class":76},"Hadassah Medical Organization","OTHER",{"id":78,"slug":79,"hasResults":11,"nctId":80,"briefTitle":81,"officialTitle":81,"acronym":4,"eligibilityCriteria":82,"healthyVolunteers":83,"sex":16,"minAge":84,"maxAge":4,"enrollmentInfo":85,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":87,"conditions":88,"keywords":107,"overallStatus":113,"whyStopped":4,"lastUpdateSubmitDate":114,"lastUpdatePostDateStruct":115,"startDateStruct":117,"completionDateStruct":119,"leadSponsor":121,"locationsCount":123},"100565858","the-curepsp-genetics-program-100565858","NCT06647641","The CurePSP Genetics Program","Inclusion Criteria:\n\n1. Adults (aged 35 or older) with a clinical diagnosis of PSP, CBS, MSA, or a related neurological disease as confirmed by their healthcare provider, or unaffected family members of participants who have reported a family history of relevant neurodegenerative conditions.\n2. Meet Movement Disorder Society (MDS) Clinical Diagnostic Criteria for Possible or Probable PSP (32), clinically established or clinically probable MSA (33), Armstrong criteria (2013) for possible or probable CBS (34). Diagnostic certainty will be determined by the treating\u002Freferring clinician.\n3. Willingness to undergo genetic testing. Participants will have the option to receive relevant genetic test results.\n4. Have the capacity to give full informed consent in writing or electronically, or provide consent through a legally authorized representative (LAR)\u002Fpower of attorney (POA), and have read, understood, and completed the informed consent form.\n5. Are able to perform or have a designee who can perform study activities (including completion of either online or orally administered surveys).\n\nExclusion Criteria:\n\n1. Individuals who have received a blood transfusion within the past 3 months.\n2. Individuals who have active hematologic malignancies such as lymphoma or leukemia.\n3. Individuals who have had a bone marrow transplant within the past 5 years.\n4. Individuals under the age of 35 or age of majority in applicable states at the time of consenting.",true,"35 Years",{"count":86,"type":21},1000,"This study is an observational, prospective genetic study. It aims to obtain DNA for research and testing from patients with PSP, CBS, MSA, and related neurological conditions and their families.\n\nUp to 1,000 adults who have been clinically diagnosed with PSP, CBS, MSA, or related neurological conditions will be enrolled. The study intervention involves sequencing of participant blood samples using non-CLIA-approved whole genome sequencing at the National Institutes of Health. Pathogenic variants that are deemed possibly related to these conditions will be confirmed using CLIA-approved testing. The study involves minimal risk to participants.",[27,89,90,91,92,93,94,95,96,97,98,99,100,101,102,103,104,105,25,106],"PSP - Progressive Supranuclear Palsy","Corticobasal Syndrome","Corticobasal Syndrome(CBS)","Corticobasal Degeneration Syndrome","Corticobasal Degeneration","Corticobasal Degeneration (CBD)","Corticobasal Syndrome (CBS)","MSA","MSA - Multiple System Atrophy","MSA-C","Multiple System Atrophy","Multiple System Atrophy (MSA) With Orthostatic Hypotension","Multiple System Atrophy - Cerebellar Subtype (MSA-C)","Multiple System Atrophy - Parkinsonian Subtype (MSA-P)","Multiple System Atrophy, Cerebellar Type","Multiple System Atrophy, Parkinsonian Type","Progressive Supranuclear Palsy","Progressive Supranuclear Palsy (PSP)",[108,105,99,109,110,27,96,111,112],"genetic study","Corticobasal","CurePSP","CBD","Genes","RECRUITING","2026-01-12",{"date":116,"type":34},"2026-01-14",{"date":118,"type":34},"2024-10-08",{"date":120,"type":21},"2030-12-31",{"name":122,"class":76},"Massachusetts General Hospital",1,{"id":125,"slug":126,"hasResults":11,"nctId":127,"briefTitle":128,"officialTitle":128,"acronym":129,"eligibilityCriteria":130,"healthyVolunteers":11,"sex":16,"minAge":52,"maxAge":4,"enrollmentInfo":131,"targetDuration":4,"studyType":54,"phases":133,"briefSummary":134,"conditions":135,"keywords":4,"overallStatus":113,"whyStopped":4,"lastUpdateSubmitDate":143,"lastUpdatePostDateStruct":144,"startDateStruct":146,"completionDateStruct":148,"leadSponsor":150,"locationsCount":123},"100617268","repetitive-transcranial-magnetic-stimulation-in-frontotemporal-lobar-degeneration-100617268","NCT07316413","Repetitive Transcranial Magnetic Stimulation in Frontotemporal Lobar Degeneration","FTLD_rTMS","Inclusion Criteria:\n\n* diagnosis of FTLD (bvFTD, avPPA, svPPA, CBS, or PSP)\n* global CDR plus NACC FTLD ≤ 1\n\nExclusion Criteria:\n\n* presence of cerebrovascular disease, hydrocephalus, intracranial masses identified by MRI, history of head trauma, serious medical conditions unrelated to FTLD, history of epilepsy, and presence of electronic (e.g., pacemaker) or metallic implants in the head.",{"count":132,"type":21},120,[56],"The aim of the study is to evaluate the safety, feasibility, clinical and biological efficacy, and predictors of efficacy of an intervention consisting of repetitive transcranial magnetic stimulation (rTMS) in patients with frontotemporal dementia (FTLD) or in asymptomatic persons at risk of FTLD (i.e., persons familiar with FTLD patients).\n\nrTMS is a non-invasive brain stimulation technique, and has demonstrated the ability to modulate neuronal activity by applying high-frequency magnetic fields to the surface of the skull. rTMS offers a potentially effective means to influence neural networks involved in the pathogenesis of neurodegenerative diseases, with benefits that could extend beyond symptomatic relief. Its safety has been widely documented in a variety of clinical conditions, making it an ideal candidate for application in neurodegenerative diseases.\n\nIn the present study, participants will undergo the following procedures: (i) clinical and neuropsychological assessment, (ii) TMS, and (iii) blood sampling. The occurrence of adverse events will be monitored throughout the duration of the study.\n\nThe study is structured in two phases. In the first phase, double-blind, randomised and placebo-controlled, participants will be randomised into two groups: group 1, participants will receive real rTMS for 2 weeks; and group 2, placebo rTMS for 2 weeks. In the second, open-label phase, after 10 weeks, both group 1 and group 2 participants will receive real rTMS for 2 weeks. Each participant will receive a total of 4 weeks of intervention (4 weeks of real stimulation in group 1, or 2 weeks of real stimulation and 2 weeks of placebo stimulation in group 2), with 5 sessions per week (Monday to Friday) lasting approximately 30 minutes each.\n\nVisits will take place at the beginning of the study (T00) and after 2 weeks (T02, end of the first phase), 12 weeks (T12, beginning of the second phase), 14 weeks (T14, end of the second phase), 24 weeks (T24, follow-up). During each visit, participants underwent the following procedures: (i) clinical and neuropsychological assessment, (ii) blood sampling, and (iii) TMS. Specific biomarker analyses will be performed on the blood samples to study the pathophysiological mechanisms of the disease and the effect of the experimental intervention.",[136,137,138,139,27,140,141,142],"FTLD","FTD","bvFTD","PPA","Cortical Basal Syndrome (CBS)","rTMS","Theta Burst Stimulation","2025-12-18",{"date":145,"type":34},"2026-01-05",{"date":147,"type":34},"2025-02-13",{"date":149,"type":21},"2029-02-01",{"name":151,"class":76},"Università degli Studi di Brescia"]